# AnaptysBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anaptysbio

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.anaptysbio.com
- Total disclosed funding: $85M
- Latest round: Series D (Jul 15, 2015)
- Investors on record: 11

## About

AnaptysBio, Inc. is a biotechnology firm focused on developing innovative immunology therapeutics targeting autoimmune diseases through advanced clinical solutions and research.Founded in 2005 and headquartered in San Diego, US, AnaptysBio, Inc. specializes in developing immunology therapies. The company held an IPO on January 25, 2017, raising USD 75 mn. The current CEO is Hamza Suria.AnaptysBio, Inc. develops innovative immunology therapeutics, including rosnilimab, which targets PD-1+ T cells and is in clinical trials for rheumatoid arthritis and ulcerative colitis. Their products are aimed at healthcare providers in North America and Europe.In the most recent year, 2024, AnaptysBio reported a revenue of USD 91.28 mn, while also recording an EBITDA of USD -114.95 mn.AnaptysBio, Inc. plans to leverage its recent IPO funding of USD 75 mn to expand its therapeutic pipeline, including the upcoming launch of additional products and potential geographic expansion into Asian markets by 2025. The company aims to utilize strategic partnerships for further development and commercialization of its therapies.

## Funding rounds

- Series D, Jul 15, 2015, $40M — Frazier Healthcare Partners, HBM Partners, Novo Holdings, Cormorant Asset Management, BVF Partners, BioMed Ventures
- Series C, Oct 5, 2011, $8M — Alloy Ventures, Frazier Healthcare Partners, Avalon Ventures, Novo Holdings
- Series B, Aug 25, 2008, $0.5M — Alloy Ventures, Avalon Ventures, Novo Holdings A/S
- Series B, Nov 8, 2007, $34M — Alloy Ventures, Frazier Healthcare Partners, Avalon Ventures, WS Investments, Novo Holdings A/S, Numenor Ventures
- Series A, Aug 22, 2006, $2M — Avalon Ventures

## Investors

- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series A, Series B, Series C
- Alloy Ventures (https://capitalatlas.ai/funds/alloy-ventures) — Series B, Series C
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series B, Series C, Series D
- WS Investments (https://capitalatlas.ai/funds/ws-investments) — Series B
- Novo Holdings A/S — Series B
- Numenor Ventures (https://capitalatlas.ai/funds/numenor-ventures) — Series B
- Novo Holdings — Series C, Series D
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series D
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series D
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series D
- BioMed Ventures — Series D